Still in search of a herbal medicine: Culprit is poor methodological quality of research Sir, I read the editorial "Still in search of a herbal medicine…" by Thatte. [1] She mentioned that "in spite of increasing research in herbal medicines… there is still no product, no drug, that has made a difference to therapeutics". She mentioned various problems inherently associated with herbal research such as identification of plants, standardization, toxicological data etc. I believe something else we should not overlook is "methodological problems associated with the animal studies". Studies show that animal studies are poor predictors of effects in humans. [2] Among 20 reviews examining clinical utility, animal models demonstrated the potential to contribute significantly toward the development of human clinical interventions in only two cases. [3] There are various types of methodological problems associated with these studies. Some of these are as follows: [2] • Disparate animal species and strains.
• Different models for inducing illness or injury with varying similarity to the human condition.
• Variations in drug dosing schedules and regimen that are of uncertain relevance to the human condition.
• Variability in the way animals are selected for study.
• Methods of randomization.
• Choice of comparison therapy (none, placebo, vehicle).
• Reporting of loss to follow-up.
• Small experimental groups with inadequate power.
• Simplistic statistical analysis that does not account for potential confounding.
• Failure to follow intention to treat principles.
• Nuances in laboratory technique that may influence results may be neither recognized nor reported-e.g. methods for blinding investigators and selection of a variety of outcome measures, which may be disease surrogates or precursors and which are of uncertain relevance to the human clinical condition, etc. I observed that in 2007 and 2008 among the articles published in IJP 84% were animal studies and many of the studies incorporated one of the problems mentioned above, such as randomization and blinding which can easily be done in animal experiments. Unfortunately either randomization or blinding are not done or are not declared in the many articles published in the journals. [2, 3] In clinical research where the drug is administered to the human, both randomization and blinding are very important. [4, 5] It has been shown that human clinical trials that lack randomization or blinding often overestimate the magnitude of treatment effects. [5] Animal studies that do not
Letters to the Editor
Can we prevent ondansetron induced fatal ventricular tachycardia?
Sir, We have read with interest the article 'Ondansetron induced fatal ventricular tachycardia' by Chandrakala et al., published in the Indian Journal of Pharmacology, August 2008. We would like you to give us the opportunity to discuss some of our observations on the same.
Ondansetron is a racemic compound having one chiral centre. Racemic Ondansetron is a 50:50 mixture of two enantiomers, R-Ondansetron and S-Ondansetron. In one animal study (in dogs), effects of R-Ondansetron, S-Ondansetron and racemic Ondansetron on cardiac arrhythmias (cardiotoxicity) were evaluated. QTc interval was most prolonged among animals receiving S-Ondansetron and racemic Ondansetron and was shortest among animals receiving R-Ondansetron. Based on these results it was reported that R-Ondansetron has less cardiotoxicity than S-Ondansetron or racemic Ondansetron. [1] Bodhankar et al. in 2006 studied the effect of racemic Ondansetron, R-Ondansetron and S-Ondansetron on QTc interval in electrocardiograms of rats. The Ondansetron and its enantiomers were administered IV in a dose of 3 mg/Kg and changes in QT and RR interval and heart rate were calculated. The results of this study showed that racemic Ondansetron and S-Ondansetron significantly prolonged QTc interval, while
